购物车
- 全部删除
- 您的购物车当前为空
ITPRIPL1 Protein, Human, Recombinant (hFc) is expressed in HEK293 Cells. The accession number is Q6GPH6-1.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 μg | ¥ 4,460 | 期货 | |
1 mg | 询价 | 期货 |
生物活性 | Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
产品描述 | ITPRIPL1 Protein, Human, Recombinant (hFc) is expressed in HEK293 Cells. The accession number is Q6GPH6-1. |
种属 | Human |
表达系统 | HEK293 Cells |
标签 | C-hFc |
蛋白编号 | Q6GPH6-1 |
别名 | KIAA1754L,D1B |
蛋白构建 | A DNA sequence encoding the Human ITPRIPL1 (NP_001008949.1) (His25-Gly103) was expressed with the fused Fc region of human IgG1 at the C-terminus. |
蛋白纯度 | ≥ 95% as determined by SDS-PAGE. ≥ 95% as determined by SEC-HPLC. |
分子量 | 36.03 kDa (predicted); 41.1 kDa and 36.9 kDa (reducing contition, due to glycosylation) |
内毒素 | < 1.0 EU per μg of the protein as determined by the LAL method |
缓冲液 | Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
复溶方法 | Please refer to the lot-specific COA. |
存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. |
研究背景 | Inositol 1,4,5-trisphosphate Receptor Interacting Protein-Like 1 or ITPRIPL1 is a transmembrane protein with broad expression in the testis associated with immune evasion. In fact, ITPRIPL1 is a molecule specifically expressed in immune privileged tissues, “hot” tumors without PD-L1 expression, and non-responding tumors to PD-1 blockade therapy. ITPRIPL1 has been shown to impair T cell function in vitro and in vivo through CD3e with experimental evidence supporting a negative correlation between ITPRIPL1 expression level in antigen-presenting cells and T cell cytotoxicity. ITPRIPL1 was a hypermethylated-low expression gene in breast cancer and acted as an independent biomarker for the prognosis of lung adenocarcinoma by using bioinformatics methods. Thus, targeting the ITPRIPL1-CD3e axis, especially in PD-1 - PD-L1 negative patients, is a promising therapeutic strategy to reduce immune evasion. |